EMERYVILLE, Calif., Sept. 27,
2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a
functional cell biology company, announced the Opto® Memory B
Discovery Human workflow, further expanding diversity of antibodies
customers can discover on the Beacon® optofluidic platform.
The new workflow and reagents, to be commercially available by
the end of the year, enable rapid, automated generation of
antigen-specific, functional monoclonal antibodies from human
memory B cells, building on prior workflows and reagents that used
rabbit memory B cells and mouse plasma cells. Directly accessing
the human repertoire with new workflow and reagents allows
researchers to find more physiologically relevant and efficacious
antibodies faster in a rapidly evolving biomedical field aimed at
addressing infectious, autoimmune, and oncologic diseases.
Using the Opto Memory B Discovery Human workflow, PhenomeX
estimates customers can:
- Prepare memory B cells from a wide variety of traditional
enrichment strategies for screening in <1 week;
- Screen up to 60,000 single B cells per workflow in five days,
depending on chip selection and number of chips used per
workflow;
- Identify hundreds to thousands of antigen-specific hits per
workflow; and
- Recover high-quality antibody sequences for the majority of
discovered hits.
"We are excited to announce our continued innovation that
enables antibody discovery customers to find high-value molecules
against the most difficult targets in the shortest time possible,"
said Yan Zhang, Ph.D., chief
commercial officer of PhenomeX. "Following the impacts our
optofluidic technology had in discovering molecules that helped
save lives during the onset of the COVID-19 pandemic and in
providing researchers a platform to stay ahead of the endemic
disease, we embarked on a journey to democratize a workflow that
could dramatically cut timelines and costs to address human
disease. Our customers can now rapidly screen, recover, and
sequence memory B cells from human donors with unparalleled
phenotypic depth in a single week, unlocking new research potential
and preparedness in autoimmune, oncology, and infectious
diseases."
The workflow broadens PhenomeX's market opportunity beyond
rodent models, enabling direct discovery of high-value human
antibodies that are well-suited for therapeutics, diagnostics, and
research reagents without the explicit need for experimentation in
animal models.
Read more about Opto Memory B Discovery Human workflow and other
PhenomeX antibody discovery products at our product page on
www.phenomex.com.
About PhenomeX
PhenomeX is empowering scientists to leverage the full potential of
each cell and drive the next era of functional cell biology that
will advance human health. We enable scientists to reveal the most
complete insights on cell function and obtain a full view of the
behavior of each cell. Our unique suite of proven high-throughput
tools and services offer unparalleled resolution and speed,
accelerating the insights that are key to advancing discoveries
that can profoundly improve the prevention and treatment of
disease. Our award-winning platforms are used by researchers across
the globe, including those at the top 15 global pharmaceutical
companies and approximately 85% of leading U.S. comprehensive
cancer centers.
PhenomeX has no affiliation with Phenomenex, Inc. PhenomeX will
be changing its name. All inquiries regarding Phenomenex, Inc.
and/or its products should be directed to info@phenomenex.com.
Forward-Looking Statements
To the extent that statements contained in this press release are
not descriptions of historical facts regarding PhenomeX or its
products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
PhenomeX undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-announces-opto-memory-b-discovery-human-workflow-on-the-beacon-optofluidic-platform-301940374.html
SOURCE PhenomeX